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make comparison of results between different studies 
difficult and standardization is called for.  The quantitative 
imaging biomarker alliance (QIBA) is an example of an 
initiative that aims to improve the value and practicality of 
quantitative imaging biomarkers by reducing variability 
across devices, patients and time. 
Whereas standardization in methodology is important for 
quantification, it has to be able to accommodate emerging 
new techniques. It is untenable to continue using outdated 
methods, simply because earlier studies did not have access 
to more advanced equipment. Therefore, within a 
multicenter project using quantitative MRI for imaging cancer 
in the prostate and cervix, we developed a procedure that 
allows each center to use the optimal sequences for their 
scanner. In a series of phantom and volunteer experiments 
these sequences are benchmarked against well-established 
sequences which are robust, but typically too slow for clinical 
use. Consistent quantification with a bias of a few percent 
between different scanners and institutes was feasible for T2 
mapping, as well as for diffusion-weighted MRI. With newer 
scanners and sequences typically more precise results were 
obtained. This strategy is therefore a way to achieve 
consistency between quantitative results from different 
centers and studies.  
    
SP-0292   
The issue of the quality of data in clinical trials 
P. Blanchard1 
1Institut Gustave Roussy, Radiation Oncology, Villejuif, 
France  
 
Clinical trials are considered as the most rigorous way to 
prospectively evaluate the efficacy and toxicity of 
treatments. When randomized designs are used they also 
provide comparative effectiveness between several 
therapies. Good Clinical Practice is the universal ethical and 
scientific quality standard for conducting clinical trials and 
applies to all aspects of the clinical trial process. Quality is 
viewed as a continuum, going from trial design to analysis 
and reporting. The quality of a clinical trial at an investigator 
site is usually assessed by sponsor audits and regulatory 
inspections, but radiation oncology trials can, through RTQA 
procedures, include an innovative means of quality 
assessment which can ultimately generate data and 
hypotheses. The Clinical Trials Transformation Initiative has 
defined quality as “the ability to effectively answer the 
intended question about the benefits and risks of a medical 
product (therapeutic or diagnostic) or procedure, while 
assuring protection of human subjects”. 
The different issues of quality in clinical trials will be 
discussed, including trial design, statistical hypotheses, 
interventions, data recording and monitoring, statistical 
analysis, trial reporting and interpretation. Means to improve 
trials quality and generalization of trials’ results will also be 
discussed. All the limitations to data quality in prospective 
trials described will also apply to other forms of clinical 
research, such as data-mining, and are usually minimized and 
controlled in randomized trials. It is crucial to allow external 
audit and meta-analyses, as these procedures can identify 
and potentially reduce biases. Ultimately the reader is the 
last judge of trial quality through the critical reading of 
medical literature.  
 
Symposium: Risk management: QA and safety 1  
 
 
SP-0293   
The ESTRO task force on risk management - A Status 
Report 
T. Knöös1, M. Coffey2, O. Holmberg3, E. Lartigau4, D. 
Verellen5 
1Skåne University Hospital and Lund University, Oncology and 
Radiation Physics, Malmö and Lund, Sweden  
2Trinity College, School of Radiotherapy, Dublin, Ireland 
Republic of  
3International Atomic Energy Agency (IAEA), Radiation 
Protection of Patients Unit Department of Nuclear Safety & 
Security, VIenna, Austria  
4Centre Oscar Lambret, Département Universitaire de 
Radiothérapie, Lille, France  
5Vrije Universiteit Brussel, Department of Radiotherapy, 
Brussel, Belgium  
 
Aim: ESTRO has formed a task force on risk management 
within radiation oncology (RO).  ESTRO represents all the 
professionals working within RO and is therefore the most 
appropriate partner to work with on issues relating to risk 
and risk management within radiotherapy.  One example is in 
the implementation of the latest EU directive on basic safety 
standard in radiation protection, which will make reporting 
and learning from incidents and near incidents a legal 
requirement.  ESTRO works closely with the National 
Societies in EU and is ideally positioned to inform and advise 
on this and all other related issues. 
Methods: The remit of the working group was to define the 
specific tasks that should be carried out.  These include: 
•       To develop a body of knowledge in order to position 
ESTRO such that they can inform and influence policy with 
respect to risk management in radiotherapy at the level, for 
instance of the European Commission 
•       To prepare and disseminate information to the National 
Societies and the ESTRO community on important 
developments in the area of risk management and incident 
reporting and learning that they should be aware of.   
•       To position ESTRO as an interface with other 
professional bodies such as ASTRO/AAPM to ensure 
consistency of approach internationally.   
•       To liaise between European and global bodies, the 
National Societies and the ESTRO community to advise with 
respect to effective implementation of the new EURATOM 
Directive. 
•       To carry out a scoping exercise of all the current 
activities in the area of risk management and incident 
learning specifically to identify variations and 
inconsistencies. 
 Incident Learning Systems (ILS): 
 •       ROSIS, SAFRON (IAEA) 
 •       RO-ILS (ASTRO/AAPM) 
 •       National Reporting and Learning System – 
NRLS with specific coding for RT (UK) 
 •       Canadian Partneship for Quality in 
Radiotherapy – CPQR (Ca) 
 •       Etc… 
 
Consistent with the requirements of the new EURATOM Basic 
Safety Standards which will mandate new measures in 
relation to risk management in radiotherapy, the ESTRO, as 
the European professional body in radiotherapy should be in a 
position to give direction in relation to (for example): 
What should be considered a mandatory reportable event 
Carrying out prospective analysis when new technology is 
introduced 
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Implementing a registration and analysis of events relating to 
actual or potential unintended exposure 
•       To prepare and deliver guidelines and education 
programmes to enable compliance with national legislation in 
the area 
•       To monitor European and international activities on an 
ongoing basis and update the ESTRO as appropriate 
•       To prepare and disseminate information to the public 
on how safety is already a key focus in radiotherapy generally 
and the on-going efforts to ensure safety issues remain 
central to radiotherapy practice. 
Conclusion: The aim of the task force is to position ESTRO at 
the forefront of Safety and Risk Management in radiation 
therapy by 
•       Collaboration with professional societies within first of 
all in EU/Europe but also with other organisation within RO 
•       Preparation of guidelines and educational material 
 •       Information and dissemination of present and 
future EURATOM directives.  
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Purpose: Quality and safety improvement is a 
multidimensional problem. Many recommendations for best 
practices have been put forth in the last five years. A recent 
review of seven authoritative documents revealed no fewer 
than 117 separate recommendations. These 
recommendations span the spectrum from quality control to 
prospective risk assessment to incident learning and safety 
culture. With such a wealth of information, it is challenging 
to absorb and implement quality improvement 
recommendations in a busy clinical environment. To address 
this issue, the American Association of Physicists in Medicine 
(AAPM) has developed the Safety Profile Assessment (SPA), a 
freely-available online tool designed to probe key aspects of 
quality and safety. This report describes the development of 
the SPA and its first year of use. 
Methods: The SPA was developed over a two year period by a 
multi-disciplinary panel of experts using a consensus process. 
The resulting tool consists of 92 indicator questions designed 
to gauge the most important dimensions of quality and 
safety. The SPA was pilot tested in 21 volunteer clinics and 
released for general use in July 2013. Anonymous survey data 
were collected to gauge users’ experience. The SPA was also 
analyzed with respect to the widely-accepted dimensions of 
quality from Donabedian. 
Results: In the first year of use, 107 users completed the 
SPA. The online tool provides a (graphical) benchmarking of 
answers against all other respondents in the database and the 
ability to track responses over time. An annotated 
bibliography is available for each indicator question, and the 
user can download a safety and quality tracking spreadsheet 
to guide in the implementation of improvements. Classifying 
the indicator questions according to Donabeian’s quality 
categories yielded the following results: process issues (62%), 
structural issues (27%) and outcomes (8%). In pilot testing the 
SPA required an average of 1.3 hours to complete. The 
majority of respondents (59%) had assembled a 
multidisciplinary group to complete the SPA of 3.9 members 
on average. With a 69% response rate to the survey, 
respondents indicated that SPA was easy or very easy to use 
(70%) and that they would definitely or very probably 
complete the SPA again (63%).  
Conclusions:  The Safety Profile Assessment is a freely 
available online tool intended to provide a practical means 
for assessing the quality and safety environment in a 
radiation oncology clinic. The tool has been reviewed 
favorably by the first cohort of users. 
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Purpose: The goal of the MARR project is to find a means to 
implement a risk analysis methodology among radiotherapy 
professionals. 
This project is coordinated by the Spanish Professional 
Societies of Radiotherapy Oncology (SEOR), Medical Physics 
(SEFM), Radiation Protection (SEPR) and Radiotherapy 
Technologists (AETR).  
Materials and Methods: The risk methodology chosen was the 
simplified dedicated Radiotherapy Risk Matrix and its 
associated software tool SEVRRA, developed by Foro 
Iberoamericano de Organismos Reguladores (FORO). This 
method has been proved in 44 radiotherapy services of 7 
different countries.     
The risk matrix is an easy to use semi quantitative method 
that consists in analyzing all initiating events that can lead to 
an error in the treatment if the measures put in place to 
avoid it (barriers) fail.  As a first stage in the MARR project, 
the initiating events and barriers were adapted to the 
current radiotherapy practice in Spain. 
The risk is defined as a combination of three parameters: the 
frequency of occurrence of the event, the severity of the 
potential consequences and the probability of failure of the 
set of existent barriers. The risk matrix provides the resulting 
risk level from this combination.  
The methodology allows a second deeper analysis on those 
errors resulting in a higher associated risk  
The MARR project was carried out in 10 Spanish Hospitals 
during the period 2013 -2014 and involved: 
- The training of the participating professionals (a working 
team composed by a radiotherapy oncologist –RO-, medical 
physicist –MP- and radiation therapy technologist –RTT- from 
each hospital) in the use of the risk matrix methodology and 
SEVRRA 
- The completion of the risk analysis in every hospital  
- The development of a risk analysis guide based on the 
results and the feedback provided, to facilitate the 
implementation of this method in other hospitals. 
Results: The project is finished. In the following table a list 
of the initiating events, barriers and reducers where some 
modifications were introduced as a consequence of the 
feedback from participating hospitals is shown:   
 
 
The main advantages of the methodology declared by the 
participants are: 
